Karyopharm Therapeutics (KPTI) – Hot Corp. News
-
Karyopharm Therapeutics (KPTI) receives FDA feedback that the current SIENDO study top-line results are unlikely to support an sNDA approval
-
Karyopharm Therapeutics (KPTI) CMO has stepped down to pursue other professional opportunities
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to KPTI Stock Lookup